Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Cardiac Defibrillator Implanted Under Skin Much Safer for Patients

By HospiMedica International staff writers
Posted on 02 May 2022

Implantable cardioverter defibrillators (ICDs) improve survival of patients with heart conditions but can cause perioperative complications, including perforation of heart muscle or lungs, and blood clotting in veins. More...

Now, a new type of cardiac defibrillator has been found to significantly reduce major complications for patients.

The traditional defibrillator, the transvenous ICD (TV-ICD), features a lead (a flexible wire coated with insulation) placed in the heart or the heart’s network of blood vessels. Researchers at the Population Health Research Institute (PHRI, Hamilton, ON, Canada) have demonstrated that a different type of ICD - the subcutaneous ICD (S-ICD) – in which the lead is implanted under the skin, just below the patient’s armpit, and runs along the breastbone. The S-ICD does not come into contact with any blood vessels.

Their study found that by eliminating all intra-vascular and intra-cardiac components of the ICD, the S-ICD prevents most lead-related perioperative complications, including nearly all complications which can lead to death. The study followed patients for six months after their device was implanted in 544 patients (one-quarter female) at 14 clinical sites in Canada. Half of the patients were randomized to an S-ICD; the other half to a TV-ICD. The team found that S-ICD reduced the risk of lead-related complications by 92%. Younger patients are usually under-represented in ICD trials; ATLAS S-ICD included ICD-eligible patients 18 to 60 years old (average age of 49) who had a cardiogenetic syndrome or were at high risk for lead-related complications. Follow-up of participants of ATLAS S-ICD is ongoing.

“We need to increase the statistical power of the trial to assess the comparative rates of inappropriate shocks and failed appropriate shocks, as well as the impact of ICD type on tricuspid insufficiency and heart failure,” said PHRI Senior Scientist Jeff Healey.

Related Links:
PHRI 


Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Neonatal Ventilator Simulation Device
Disposable Infant Test Lung
Head Rest
Medifa 61114_3
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: A smartphone application displays a glucose concentration that was measured using the new sensor (Photo courtesy of Chuchu Chen and Yonghao Fu)

Wearable Device for Diabetics Could Replace Continuous Glucose Monitoring Systems

Monitoring blood glucose is essential for people with diabetes to prevent complications and maintain long-term health. Current continuous glucose monitoring systems require needles inserted under the skin,... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.